294 related articles for article (PubMed ID: 25169538)
1. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
4. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
Wu Y; Liu HB; Shi XF; Song Y
PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
[TBL] [Abstract][Full Text] [Related]
5. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Wu L; Zhu J; Prokop LJ; Murad MH
Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
8. Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.
Xin WX; Fang L; Fang QL; Zheng XW; Ding HY; Huang P
Medicine (Baltimore); 2018 Mar; 97(9):e0035. PubMed ID: 29489653
[TBL] [Abstract][Full Text] [Related]
9. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh H; Singh PP; Murad MH; Limburg PJ
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2258-68. PubMed ID: 24042261
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.
Chiu CC; Huang CC; Chen YC; Chen TJ; Liang Y; Lin SJ; Chen JW; Leu HB; Chan WL
Intern Med; 2013; 52(9):939-46. PubMed ID: 23648711
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
13. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Wu MJ; Shi BM
Obes Rev; 2019 Oct; 20(10):1494-1503. PubMed ID: 31250977
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.
Liu Y; Jin PP; Sun XC; Hu TT
Saudi J Gastroenterol; 2018; 24(2):75-81. PubMed ID: 29637913
[TBL] [Abstract][Full Text] [Related]
15. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
[TBL] [Abstract][Full Text] [Related]
16. The use of metformin, sulfonylurea compounds and insulin and the risk of hip fractures in diabetic patients: a systematic review and meta-analysis of observational studies.
Bahardoust M; Yarali M; Donyadideh G; Rahimi E; Naderi D; Tehrani FM; Delpisheh A
BMC Musculoskelet Disord; 2023 May; 24(1):367. PubMed ID: 37161384
[TBL] [Abstract][Full Text] [Related]
17. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
18. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis.
Zhao Z; He X; Sun Y
Front Pharmacol; 2023; 14():1193610. PubMed ID: 37497113
[No Abstract] [Full Text] [Related]
20. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]